There is one clinical trial.
This is a Phase 2, proof of concept, randomized, placebo-controlled, multicenter study to evaluate the ability of LB1148 to attenuate pulmonary dysfunction associated with COVID-19 pneumonia. The primary objective of this study is to determine if enteral administration of LB1148 will effect disease progression in hospitalized patients with moderate to severe COVID-19 via measurement of the proportion of subjects alive and free of respiratory failure at Day 28.
Description: The proportion of subjects alive and free of respiratory failure at Day 28.Measure: Effect of LB1148 on disease progression via measurement of the proportion of patients who are alive and free of respiratory failure. Time: 28 Days
Description: Number and proportion of patients with improved clinical status as assessed by a 9-point ordinal scale of disease severity at fixed timepoints (Days 3, 5, 7, 8, 10, 14, 28)Measure: Clinical status at fixed time points Time: Measured at 3, 5, 7, 8, 10, 14 and 28 Days
Description: Length of hospital stay (live discharge)Measure: Duration of hospital stay Time: 28 Days
Description: Number and proportion of patients requiring admission to the intensive care unitMeasure: Measurement of the number and proportion of patients requiring admission to the intensive care unit (ICU) during hospitalization Time: 28 Days
Description: Length of ICU stayMeasure: Duration of ICU stay Time: 28 Days
Description: Number and proportion of patients requiring invasive mechanical ventilationMeasure: Invasive mechanical ventilation requirements Time: 28 Days
Description: Length of time patients require invasive mechanical ventilationMeasure: Duration of invasive mechanical ventilation Time: 28 Days
Description: The number and proportion of patients deceased at Day 28Measure: All-cause 28-day mortality Time: 28 Days
Description: The incidence and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)Measure: Safety and tolerability of LB1148 Time: 28 Days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports